Daniel Gioeli

List of Publications by Year
in descending order

47 papers	2,962 citations	186265 28 h-index	223800 46 g-index
49 all docs	49 docs citations	49 times ranked	3893 citing authors

#	Article	IF	Citations
1	Molecular Imaging of Prostate Cancer Targeting CD46 Using ImmunoPET. Clinical Cancer Research, 2021, 27, 1305-1315.	7.0	18
2	A detailed characterization of stepwise activation of the androgen receptor variant 7 in prostate cancer cells. Oncogene, 2021, 40, 1106-1117.	5.9	24
3	Role of the runtâ€related transcription factor (RUNX) family in prostate cancer. FEBS Journal, 2021, 288, 6112-6126.	4.7	12
4	Validation of a multicellular tumor microenvironment system for modeling patient tumor biology and drug response. Scientific Reports, 2021, 11, 5535.	3.3	4
5	IGF1R and Src inhibition induce synergistic cytotoxicity in HNSCC through inhibition of FAK. Scientific Reports, 2021, 11, 10826.	3.3	9
6	PRAS40 Phosphorylation Correlates with Insulin-Like Growth Factor-1 Receptor-Induced Resistance to Epidermal Growth Factor Receptor Inhibition in Head and Neck Cancer Cells. Molecular Cancer Research, 2020, 18, 1392-1401.	3.4	9
7	AR phosphorylation and CHK2 kinase activity regulates IR-stabilized ARâ€“CHK2 interaction and prostate cancer survival. ELife, 2020, 9, .	6.0	4
8	Discovery of a novel long noncoding RNA overlapping the LCK gene that regulates prostate cancer cell growth. Molecular Cancer, 2019, 18, 113.	19.2	10
9	Development of a multicellular pancreatic tumor microenvironment system using patient-derived tumor cells. Lab on A Chip, 2019, 19, 1193-1204.	6.0	25
10	Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology, 2018, 20, 192-202.	1.2	52
11	Î±vÎ²6 Integrin Promotes Castrate-Resistant Prostate Cancer through JNK1-Mediated Activation of Androgen Receptor. Cancer Research, 2016, 76, 5163-5174.	0.9	32
12	Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma. EBioMedicine, 2016, 10, 85-100.	6.1	56
13	Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas. Oncotarget, 2016, 7, 2734-2753.	1.8	19
14	Systems Analysis of Adaptive Responses to MAP Kinase Pathway Blockade in BRAF Mutant Melanoma. PLoS ONE, 2015, 10, e0138210.	2.5	9
15	Preventing the Androgen Receptor N/C Interaction Delays Disease Onset in a Mouse Model of SBMA. Cell Reports, 2015, 13, 2312-2323.	6.4	25
16	Cell-cycle-dependent regulation of androgen receptor function. Endocrine-Related Cancer, 2015, 22, 249-264.	3.1	30
17	Checkpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth. Cancer Research, 2015, 75, 5093-5105.	0.9	20
18	Androgen receptor phosphorylation: biological context and functional consequences. Endocrine-Related Cancer, 2014, 21, T131-T145.	3.1	105

#	Article	IF	Citations
19	The convergence of DNA damage checkpoint pathways and androgen receptor signaling in prostate cancer. Endocrine-Related Cancer, 2014, 21, R395-R407.	3.1	34
20	p70S6 kinase is a critical node that integrates HER-family and PI3 kinase signaling networks. Cellular Signalling, 2014, 26, 1627-1635.	3.6	8
21	Combinatorial drug screening identifies compensatory pathway interactions and adaptive resistance mechanisms. Oncotarget, 2013, 4, 622-635.	1.8	44
22	Synthetic Lethal Screening with Small-Molecule Inhibitors Provides a Pathway to Rational Combination Therapies for Melanoma. Molecular Cancer Therapeutics, 2012, 11, 2505-2515.	4.1	32
23	Identification of Kinases Regulating Prostate Cancer Cell Growth Using an RNAi Phenotypic Screen. PLoS ONE, 2012, 7, e38950.	2.5	51
24	Post-translational modification of the androgen receptor. Molecular and Cellular Endocrinology, 2012, 352, 70-78.	3.2	115
25	Compensatory Pathways Induced by MEK Inhibition Are Effective Drug Targets for Combination Therapy against Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics, 2011, 10, 1581-1590.	4.1	63
26	Matrix Rigidity Regulates Cancer Cell Growth and Cellular Phenotype. PLoS ONE, 2010, 5, e12905.	2.5	285
27	FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells. Molecular and Cellular Biology, 2010, 30, 1243-1253.	2.3	152
28	The promise of novel androgen receptor antagonists. Cell Cycle, 2010, 9, 440-449.	2.6	13
29	CDK9 Regulates AR Promoter Selectivity and Cell Growth through Serine 81 Phosphorylation. Molecular Endocrinology, 2010, 24, 2267-2280.	3.7	119
30	The Neuroendocrine-Derived Peptide Parathyroid Hormoneâ€“Related Protein Promotes Prostate Cancer Cell Growth by Stabilizing the Androgen Receptor. Cancer Research, 2009, 69, 7402-7411.	0.9	54
31	SUMO-Specific Protease 1 (SENP1) Reverses the Hormone-Augmented SUMOylation of Androgen Receptor and Modulates Gene Responses in Prostate Cancer Cells. Molecular Endocrinology, 2009, 23, 292-307.	3.7	93
32	Activation of the DNA-dependent Protein Kinase Stimulates Nuclear Export of the Androgen Receptor in Vitro. Journal of Biological Chemistry, 2008, 283, 10568-10580.	3.4	26
33	Signal Transduction by the Rasâ€“MAP Kinase Pathway in Prostate Cancer Progression. , 2008, , 223-256.		1
34	Integration of Rapid Signaling Events with Steroid Hormone Receptor Action in Breast and Prostate Cancer. Annual Review of Physiology, 2007, 69, 171-199.	13.1	112
35	Subcellular Localization Modulates Activation Function 1 Domain Phosphorylation in the Androgen Receptor. Molecular Endocrinology, 2007, 21, 2071-2084.	3.7	31
36	Rap2 regulates androgen sensitivity in human prostate cancer cells. Prostate, 2007, 67, 1590-1599.	2.3	25

#	Article	IF	Citations
37	Stress Kinase Signaling Regulates Androgen Receptor Phosphorylation, Transcription, and Localization. Molecular Endocrinology, 2006, 20, 503-515.	3.7	163
38	Receptor for Activated C Kinase 1 (RACK1) and Src Regulate the Tyrosine Phosphorylation and Function of the Androgen Receptor. Cancer Research, 2006, 66, 11047-11054.	0.9	103
39	Signal transduction in prostate cancer progression. Clinical Science, 2005, 108, 293-308.	4.3	103
40	Simian Virus 40 Small t Antigen Mediates Conformation-Dependent Transfer of Protein Phosphatase 2A onto the Androgen Receptor. Molecular and Cellular Biology, 2005, 25, 1298-1308.	2.3	61
41	Transient, Ligand-Dependent Arrest of the Androgen Receptor in Subnuclear Foci Alters Phosphorylation and Coactivator Interactions. Molecular Endocrinology, 2004, 18, 834-850.	3.7	62
42	Ras signaling in prostate cancer progression. Journal of Cellular Biochemistry, 2004, 91, 13-25.	2.6	146
43	The Androgen Receptor Acetylation Site Regulates cAMP and AKT but Not ERK-induced Activity. Journal of Biological Chemistry, 2004, 279, 29436-29449.	3.4	74
44	Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-2 prostate cancer cells. Cancer Research, 2003, 63, 1975-80.	0.9	66
45	Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Research, 2003, 63, 1981-9.	0.9	157
46	Androgen Receptor Phosphorylation. Journal of Biological Chemistry, 2002, 277, 29304-29314.	3.4	299
47	Immunostaining for activated extracellular signal-regulated kinases in cells and tissue. Methods in Enzymology, 2001, 332, 343-353.	1.0	7